Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
In a phase 1/2 trial the oral BCR-ABL1 TK inhibitor had effect even in patients with ponatinib-resistant disease.
ASC4FIRST Trial: Asciminib Shows Favorable Safety, Efficacy Versus Investigator-Selected TKIs in CML
Asciminib showed superior safety and efficacy compared with standard-of-care, second-generation, investigator-selected TKIs.
Pirtobrutinib cut disease progression/death risk by 46% vs IdealaR/BR in heavily pretreated relapsed/refractory CLL/SLL.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
The approval is based on results of the ASC4FIRST trial, which compared asciminib versus investigator-selected TKIs.
Ponatinib demonstrated long-term efficacy and manageable safety in patients with highly resistant, chronic phase CML.
Achieving deep molecular response has allowed for treatment discontinuation, making TFR a main goal of therapy.
Olverembatinib was well tolerated and showed strong antileukemic activity in patients with chronic phase CML.
Asciminib continues to demonstrate favorable safety and tolerability compared to TKIs in patients with chronic phase CML.
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
The rate of response was “significantly higher” with asciminib compared with tyrosine kinase inhibitors.
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.